Called one of the 50 most influential people in Regenerative Medicine, Eduardo Bravo is currently the CEO of Nordic Nanovector, a company focused on a unique combo therapy combining a monoclonal antibody with a radiation therapy. He successfully steered the stem cell company TiGenix through a rejected FDA application and re-emerge with a new product portfolio to be successfully acquired in 2018 by Takeda in an all cash deal valued over $600 mil. Eduardo is also the former president of the trade body European Biopharmaceutical Enterprises (EBE), and led several initiatives to help Europe’s competitiveness in the biotech sector. In this podcast we discuss the looming international debates on drug pricing as well as the challenges to commercialisation in Europe.

See omnystudio.com/listener for privacy information.